AI-generated summary
The authors report testing a transferrin-coated graphene oxide carrier loaded with doxorubicin for treating glioma, combining chemotherapy with photothermal therapy. In cell and rat studies, they describe improved drug crossing of the blood brain barrier, higher glioma cell death, and longer survival compared with doxorubicin alone or without transferrin. The abstract does not report human testing.
- Who or what was studied
- Glioma cells in vitro and glioma-bearing rats in vivo
- Limits stated in the abstract
- The abstract reports only in vitro and rat experiments, with no human data and no sample sizes or statistical details stated.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.